Compare Biogen Inc (BIIB) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Public Storage — how do they compare? Biogen Inc trades at $196 (market cap $28.34B), while Public Storage trades at $317.13 (market cap $56.00B). The key difference: Public Storage is the larger of the two by market cap, and Public Storage pays a 3.76% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PSA | |
|---|---|---|
Market Cap | $28.34B | $56.00B |
Sector | Health | Real Estate |
52-Week High | $216.63 | $329.64 |
52-Week Low | $122.68 | $258.44 |
Enterprise Value | $30.62B | $70.25B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Public Storage (PSA) trades at $321.86, up 0.41% on the day, with a neutral technical signal and strong profitability metrics including a 39.16% net income margin and 33.78% ROE. Recent earnings beats and the pending acquisition of National Storage Affiliates highlight strategic growth initiatives, supported by a $3.00 dividend and robust cash flow from operations of $3.19B in 2025.
The outlook is positive with a consensus price target of $332.25, though elevated valuation ratios (P/E 33.25) and integration risks from acquisitions pose challenges. Earnings growth and market expansion into Canada are key catalysts, while interest rate sensitivity and competitive pressures remain watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
